VRTX

Vertex Pharmaceuticals
D

VRTX

391.20
USD
2.12
(0.54%)
مفتوح الان
حجم التداول
19,294
الربح لكل سهم
18
العائد الربحي
-
P/E
28
حجم السوق
100,300,022,671
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ سنة
buy
2024-08-22 05:31
VRTX Chart
المزيد
أصول ذات صلة
ABBV
ABBV
-1.130
(-0.54%)
206.870 USD
AMGN
AMGN
-2.43
(-0.84%)
285.38 USD
BIIB
BIIB
-2.390
(-1.75%)
133.880 USD
BMRN
BMRN
-1.160
(-1.98%)
57.500 USD
GILD
GILD
-0.700
(-0.61%)
113.210 USD
INCY
INCY
-0.960
(-1.13%)
83.890 USD
LLY
LLY
-0.52
(-0.07%)
729.71 USD
REGN
REGN
-8.43
(-1.44%)
578.03 USD
المزيد
الأخبار المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.